http://support.dalton.missouri.edu/index.php/daltonnews News articles for the Dalton Cardiovascular Research Center en mcclaskeyl@missouri.edu Copyright 2009 2009-10-01T18:17:05+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/dalton_newsletter/ http://support.dalton.missouri.edu/index.php/daltonnews/dalton_newsletter/#When:18:17:05Z daltonnews_10_09.pdf Click here for our October Newsletter]]> 2009-10-01T18:17:05+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/srikanth_ella_a_doctoral_student_in_biological_engineering/ http://support.dalton.missouri.edu/index.php/daltonnews/srikanth_ella_a_doctoral_student_in_biological_engineering/#When:16:27:38Z http://engineering.missouri.edu/news/stories/2009/SrikanthElla/index.php


Click here for story]]> 2009-09-11T16:27:38+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/july_newsletter/ http://support.dalton.missouri.edu/index.php/daltonnews/july_newsletter/#When:13:33:50Z daltonnewsletter_07_09.pdf]]> 2009-08-03T13:33:50+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/catharine_g_clark_mwa_spring_09_predoctoral_fellowship_awardee/ http://support.dalton.missouri.edu/index.php/daltonnews/catharine_g_clark_mwa_spring_09_predoctoral_fellowship_awardee/#When:18:49:45Z
This award started 7/1/09 - 6/30/10 for period one. Period two runs 7/1/10-6/30/11.

Congratulations to Catharine!]]> 2009-07-13T18:49:45+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/asian_spice_could_reduce_breast_cancer_risk_in_postmenopausal_women_exposed/ http://support.dalton.missouri.edu/index.php/daltonnews/asian_spice_could_reduce_breast_cancer_risk_in_postmenopausal_women_exposed/#When:18:18:40Z
Story Contact: Kelsey Jackson, (573) 882-8353, JacksonKN@missouri.edu

COLUMBIA, Mo. - Previous studies have found that postmenopausal women who have taken a combined estrogen and progestin hormone replacement therapy have increased their risk of developing progestin-accelerated breast tumors. Now, University of Missouri researchers have found that curcumin, a popular Indian spice derived from the turmeric root, could reduce the cancer risk for women after exposure to hormone replacement therapy.

"Approximately 6 million women in the United States use hormone replacement therapy to treat the symptoms of menopause," said Salman Hyder, the Zalk Endowed Professorship in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "This exposure to progestin will predispose a large number of post-menopausal women to future development of breast cancer. The results of our study show that women could potentially take curcumin to protect themselves from developing progestin-accelerated tumors."

In the study, researchers found that curcumin delayed the first appearance, decreased incidence and reduced multiplicity of progestin-accelerated tumors in an animal model. Curcumin also prevented the appearance of gross morphological abnormalities in the mammary glands. In previous studies, MU researchers showed that progestin accelerated the development of certain tumors by increasing production of a molecule called VEGF that helps supply blood to the tumor. By blocking the production of VEGF, researchers could potentially reduce the proliferation of breast cancer cells. Curcumin inhibits progestin-induced VEGF secretion from breast cancer cells, Hyder said.

"Curcumin and other potential anti-angiogenic compounds should be tested further as dietary chemopreventive agents in women already exposed to hormone replacement therapy containing estrogen and progestin in an effort to decrease or delay the risk of breast cancer associated with combined hormone replacement therapy," Hyder said.

The study, "Curcumin delays development of MPA-accelerated DMBA-induced mammary tumors," has been accepted for publication in Menopause, a journal of the North American Menopause Society. It was coauthored by Hyder; Candace Carroll, graduate student of biomedical sciences; Cynthia Besch-Williford, associate professor of veterinary pathobiology in the MU College of Veterinary Medicine; and Mark Ellersieck, professor and researcher in the MU Experiment Station Statistics.]]> 2009-07-13T18:18:40+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/candace_carroll_selected_as_interview_candidate/ http://support.dalton.missouri.edu/index.php/daltonnews/candace_carroll_selected_as_interview_candidate/#When:20:47:02Z 2009-06-01T20:47:02+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/dcrc_welcomes_visiting_professor_kimberly_reeves/ http://support.dalton.missouri.edu/index.php/daltonnews/dcrc_welcomes_visiting_professor_kimberly_reeves/#When:14:47:04Z
Dr. Reeves will be working in Dr. Gerald Meininger's lab for approximately 5 weeks. The British Association for Cancer Research awarded Dr. Reeves a travel fellowship. The object of this travel fellowship is to gain experience in and perform initial studies using fluorescent imaging in combination with Atomic Force Microscopy (AFM) to determine prostate tumour cell adhesion molecule characteristics in the bone microenvironment at the Dalton Cardiovascular Research Center, University of Missouri, Columbia, USA. The mechanisms of bone metastasis in prostate cancer have yet to be fully elucidated, hence improving our understanding of the molecules important in this process is a prerequisite to designing specific targeted therapies. This imaging technology modified for use in the microvasculature is not available in the UK and will allow evaluation of the key molecules involved in prostate tumour cell homing and adhesion to the bone microvasculature. Experience will also be gained in Total Internal Reflection Fluorescence (TIRF) and Forster Resonance Energy Transfer (FRET). The proposed programme of research will provide preliminary data in support of a collaborative research project and funding application between the Brown and Meininger laboratories, the aim of which is to use possible adhesion/chemoattractant receptor molecules as targeted treatment for prostate cancer metastasis.]]> 2009-05-08T14:47:04+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/indira_benakanakere_phd_invited_to_endo_09_presidential_poster_competition/ http://support.dalton.missouri.edu/index.php/daltonnews/indira_benakanakere_phd_invited_to_endo_09_presidential_poster_competition/#When:18:12:11Z
Presidential Poster Competition participants will present their posters and must be present at the poster presentation to discuss their research and answer questions from the judges. Two to three expert judges will visit each of the posters. Based on the judges’ evaluations, winners will be selected from each category. Winners will be announced at the morning plenary sessions and published on the Society’s website.

Winners will receive a certificate commemorating the prestigious accolade and should remember to add it to their curriculum vitae.]]> 2009-04-29T18:12:11+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/dcrc_april_newsletter/ http://support.dalton.missouri.edu/index.php/daltonnews/dcrc_april_newsletter/#When:13:37:57Z daltonnews_04_09.pdf]]> 2009-03-31T13:37:57+00:00 http://support.dalton.missouri.edu/index.php/daltonnews/april_wellness_newsletter/ http://support.dalton.missouri.edu/index.php/daltonnews/april_wellness_newsletter/#When:20:20:40Z April_Wellness_Newsletter.pdf]]> 2009-03-25T20:20:40+00:00